Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect

Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11.

Authors

Jessica Liegel¹, Elizabeth Courville², Zohar Sachs¹, Celalettin Ustun³

Affiliations

¹ Division of Hematology-Oncology and Transplantation, Department of Medicineand, Minneapolis, MN, USA.
² Department of Pathology and Laboratory Medicine University of Minnesota, Minneapolis, MN, USA.
³ Division of Hematology-Oncology and Transplantation, Department of Medicineand, Minneapolis, MN, USA [email protected].

No abstract available

Keywords: myeloid maturation; sorafenib; tyrosine kinase inhibitors.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Bone Marrow / drug effects
Bone Marrow / pathology
Female
Gene Duplication*
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy
Male
Middle Aged
Mutation
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Recurrence
Retreatment
Sorafenib
Tandem Repeat Sequences*
Transplantation, Homologous
Treatment Outcome
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Antineoplastic Agents
Phenylurea Compounds
Protein Kinase Inhibitors
Niacinamide
Sorafenib
fms-Like Tyrosine Kinase 3